ATE393220T1 - Antisense-therapie für hormonregulierte tumoren - Google Patents

Antisense-therapie für hormonregulierte tumoren

Info

Publication number
ATE393220T1
ATE393220T1 AT00947725T AT00947725T ATE393220T1 AT E393220 T1 ATE393220 T1 AT E393220T1 AT 00947725 T AT00947725 T AT 00947725T AT 00947725 T AT00947725 T AT 00947725T AT E393220 T1 ATE393220 T1 AT E393220T1
Authority
AT
Austria
Prior art keywords
tumors
seq
odn
igfbp
mammals
Prior art date
Application number
AT00947725T
Other languages
English (en)
Inventor
Martin Gleave
Hideaki Miyake
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE393220T1 publication Critical patent/ATE393220T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00947725T 1999-07-19 2000-07-19 Antisense-therapie für hormonregulierte tumoren ATE393220T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14449599P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
ATE393220T1 true ATE393220T1 (de) 2008-05-15

Family

ID=22508861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00947725T ATE393220T1 (de) 1999-07-19 2000-07-19 Antisense-therapie für hormonregulierte tumoren

Country Status (13)

Country Link
US (1) US7297684B1 (de)
EP (1) EP1200579B1 (de)
JP (1) JP5121106B2 (de)
KR (2) KR100856475B1 (de)
AT (1) ATE393220T1 (de)
AU (1) AU772480B2 (de)
CA (1) CA2375467C (de)
DE (1) DE60038680T2 (de)
HU (1) HU228465B1 (de)
IL (2) IL146565A0 (de)
NO (1) NO332388B1 (de)
NZ (1) NZ516701A (de)
WO (1) WO2001005435A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR633101A0 (en) * 2001-07-13 2001-08-02 University Of Sydney, The Method
NZ577565A (en) * 2001-10-09 2010-10-29 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2003062421A1 (en) * 2002-01-17 2003-07-31 The University Of British Columbia Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
NZ538841A (en) 2002-10-02 2006-10-27 Univ British Columbia Compositions for reducing hsp27 for the treatment of prostate and other cancers
WO2005030260A1 (en) * 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
AU2005266948A1 (en) * 2004-07-23 2006-02-02 Pacific Edge Biotechnology Ltd. Urine markers for detection of bladder cancer
US9381209B2 (en) 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy
JP5390179B2 (ja) * 2008-12-24 2014-01-15 花王株式会社 Ｉｇｆｂｐ−５発現抑制剤
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2024214933A1 (ko) * 2023-04-13 2024-10-17 한양대학교 에리카산학협력단 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법
WO2025234704A1 (ko) * 2024-05-07 2025-11-13 오토텔릭바이오 주식회사 안티센스 올리고뉴클레오타이드 및 항암제를 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090705A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
PT98805B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Also Published As

Publication number Publication date
EP1200579B1 (de) 2008-04-23
CA2375467C (en) 2013-10-29
NO20020259L (no) 2002-01-17
KR20020033735A (ko) 2002-05-07
KR20070036180A (ko) 2007-04-02
IL146565A (en) 2012-02-29
NO20020259D0 (no) 2002-01-17
NO332388B1 (no) 2012-09-10
IL146565A0 (en) 2002-07-25
DE60038680D1 (de) 2008-06-05
NZ516701A (en) 2004-11-26
JP5121106B2 (ja) 2013-01-16
US7297684B1 (en) 2007-11-20
DE60038680T2 (de) 2009-05-07
HUP0201868A2 (en) 2002-12-28
KR100779752B1 (ko) 2007-11-27
EP1200579A2 (de) 2002-05-02
KR100856475B1 (ko) 2008-09-08
AU772480B2 (en) 2004-04-29
JP2003504418A (ja) 2003-02-04
AU6144500A (en) 2001-02-05
WO2001005435A2 (en) 2001-01-25
HU228465B1 (en) 2013-03-28
WO2001005435A3 (en) 2001-03-22
CA2375467A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
DE60038680D1 (de) Antisense-therapie für hormonregulierte tumoren
NO20014058L (no) TRPM-2-antisense-terapi
RO93650B (ro) Procedeu pentru obtinerea unei polipeptide umane fiziologic activa
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
EP0702563A4 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
WO2003090512A3 (en) Regeneration of endogenous myocardial tissue by induction of neovascularization
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
AU2003296958A8 (en) Therapeutic retroviral vectors for gene therapy
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
DK1033972T3 (da) Medikamenttilførselssystem med totrinsmålretning
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
GB9323008D0 (en) Improvements relating to cancer therapy
MY134778A (en) Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
DE60144525D1 (de) Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
BR9912279A (pt) Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas
TW200504210A (en) A nucleolin antisense inhibiting growth of cancer cell
WO2001087039A3 (en) Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
ATE552887T1 (de) Tumorspezifischer vektor für die gentherapie
CN107875402B (zh) 一种靶向基因UBE2J2的修饰siRNA的用途
WO2000071155A3 (en) New vaccine formulations - 2
EP1346045A4 (de) Menschliches protoonkogen und darin codiertes protein
Sikora et al. Genetic drug activation strategies for breast cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties